Objective: To study the effect of danhong injection combined with nadroparin calcium on serum CyS-C, CRP, IL-6, vWF, ET and VEGF in patients with acute coronary syndrome. Methods: A total of 80 patients with acute cor...Objective: To study the effect of danhong injection combined with nadroparin calcium on serum CyS-C, CRP, IL-6, vWF, ET and VEGF in patients with acute coronary syndrome. Methods: A total of 80 patients with acute coronary syndrome in our hospital from July 2014 to July 2017 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group was treated with xuesaitong injection combined with nadroparin calcium;the treatment group was treated with danhong injection combined with nadroparin calcium. The two groups were treated for 2 weeks. The serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups before and after treatment were compared. Results: There were no significantly differences of the serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups before treatment. The serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups after treatment were significantly lower than before treatment, and that of the treatment group were significantly better than that of the control group. Conclusion: Danhong injection combined with nadroparin calcium can significantly reduce the serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of patients with acute coronary syndrome, and it was worthy clinical application.展开更多
Background American College of Cardiology/American Heart Association/European Society of Cardiology （ACC/AHA/ESC） guidelines gave fondaparinux a class Ⅰ recommendation for use in patients with non-ST elevation acut...Background American College of Cardiology/American Heart Association/European Society of Cardiology （ACC/AHA/ESC） guidelines gave fondaparinux a class Ⅰ recommendation for use in patients with non-ST elevation acute coronary syndromes （NSTE-ACS） undergoing invasive or conservative strategy. Nadroparin is one of the common anticoagulants used in NSTE-ACS in China. Accordingly, this study compared the safety and efficacy between fondaparinux and nadroparin in patients with NSTE-ACS.Methods In this prospective, randomized, open-label, and single center study, a total of 300 patients with NSTE-ACS were randomized to receive either fondaparinux （group F, n=150, 2.5 mg/d） or nadroparin （group N, n=150, 0.1 ml/10 kgq12 h） for a mean of 4 days. The primary safety endpoint was the incidence of major or minor bleeding at 9 days that was not related to coronary artery bypass grafting （CABG）. The primary efficacy endpoints included death, myocardial infarction, or recurrent ischemia at 9 days. All patients underwent a 180-day follow-up.Results Baseline characteristics were well matched between the two groups. There was a non-significant 28% relative risk reduction in the primary safety endpoint in group F compared with group N （4.7% vs. 6.7%, HR 0.72, 95% CI0.42-1.65, P=0.38）. The primary efficacy endpoint was 8.0% in group F and 10.0% in group N （HR, 0.82, 95% CI0.54-1.71, P=0.49）. The composite of the safety and efficacy endpoints at 9 days （10.0% vs. 16.0%, HR 0.61, 95% CI0.31-1.10,P=0.10）, 30 days （14.0% vs. 17.9%, HR 0.72, 95% C/0.47-1.16, P=0.21）, or 180 days （18.7% vs. 27.3%, HR0.65, 95% CI0.38-1.11, P=0.11） showed a non-significant trend toward a lower value in group F.Conclusion Fondaparinux resulted in a nonsignificant risk reduction in patients with NSTE-ACS in both bleeding and ischaemic events during short- and long-term follow-up compared with nadroparin.展开更多
基金Project of Jiangsu Natural Science Foundation of China(BK2012561).
文摘Objective: To study the effect of danhong injection combined with nadroparin calcium on serum CyS-C, CRP, IL-6, vWF, ET and VEGF in patients with acute coronary syndrome. Methods: A total of 80 patients with acute coronary syndrome in our hospital from July 2014 to July 2017 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group was treated with xuesaitong injection combined with nadroparin calcium;the treatment group was treated with danhong injection combined with nadroparin calcium. The two groups were treated for 2 weeks. The serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups before and after treatment were compared. Results: There were no significantly differences of the serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups before treatment. The serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups after treatment were significantly lower than before treatment, and that of the treatment group were significantly better than that of the control group. Conclusion: Danhong injection combined with nadroparin calcium can significantly reduce the serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of patients with acute coronary syndrome, and it was worthy clinical application.
文摘Background American College of Cardiology/American Heart Association/European Society of Cardiology （ACC/AHA/ESC） guidelines gave fondaparinux a class Ⅰ recommendation for use in patients with non-ST elevation acute coronary syndromes （NSTE-ACS） undergoing invasive or conservative strategy. Nadroparin is one of the common anticoagulants used in NSTE-ACS in China. Accordingly, this study compared the safety and efficacy between fondaparinux and nadroparin in patients with NSTE-ACS.Methods In this prospective, randomized, open-label, and single center study, a total of 300 patients with NSTE-ACS were randomized to receive either fondaparinux （group F, n=150, 2.5 mg/d） or nadroparin （group N, n=150, 0.1 ml/10 kgq12 h） for a mean of 4 days. The primary safety endpoint was the incidence of major or minor bleeding at 9 days that was not related to coronary artery bypass grafting （CABG）. The primary efficacy endpoints included death, myocardial infarction, or recurrent ischemia at 9 days. All patients underwent a 180-day follow-up.Results Baseline characteristics were well matched between the two groups. There was a non-significant 28% relative risk reduction in the primary safety endpoint in group F compared with group N （4.7% vs. 6.7%, HR 0.72, 95% CI0.42-1.65, P=0.38）. The primary efficacy endpoint was 8.0% in group F and 10.0% in group N （HR, 0.82, 95% CI0.54-1.71, P=0.49）. The composite of the safety and efficacy endpoints at 9 days （10.0% vs. 16.0%, HR 0.61, 95% CI0.31-1.10,P=0.10）, 30 days （14.0% vs. 17.9%, HR 0.72, 95% C/0.47-1.16, P=0.21）, or 180 days （18.7% vs. 27.3%, HR0.65, 95% CI0.38-1.11, P=0.11） showed a non-significant trend toward a lower value in group F.Conclusion Fondaparinux resulted in a nonsignificant risk reduction in patients with NSTE-ACS in both bleeding and ischaemic events during short- and long-term follow-up compared with nadroparin.
